Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation

Diabetes Care

Volumn 38, Issue 7, 2015, Pages 1383-1392

  Chakera, Ali J ^a,b   Steele, Anna M ^a   Gloyn, Anna L ^c,d   Shepherd, Maggie H ^a   Shields, Beverley ^a   Ellard, Sian ^a   Hattersley, Andrew T ^a,b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL;

BIRTH WEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; FAMILY COUNSELING; FETUS GROWTH; FOLLOW UP; GCK GENE; GENE MUTATION; GENETIC SCREENING; GLUCOSE HOMEOSTASIS; HETEROZYGOTE; HUMAN; HYPERGLYCEMIA; INCIDENCE; INHERITANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MICROALBUMINURIA; MICROANGIOPATHY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREVALENCE; PROGENY; RETINOPATHY; REVIEW; SCREENING; DIABETES MELLITUS, TYPE 2; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; MUTATION; PREGNANCY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GENETIC TESTING; GLUCOKINASE; HETEROZYGOTE; HUMANS; HYPERGLYCEMIA; MUTATION; PREGNANCY; PREVALENCE;

EID: 84958641227     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2769     Document Type: Review

References (91)

1. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:162-164
2. Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-1310
3. Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993;328:697-702
4. Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 1998;47:307-315
5. Nolan CJ, Prentki M. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol Metab 2008;19:285-291
6. Matschinsky FM. Evolution of the glucokinase glucose sensor paradigm for pancreatic beta cells. Diabetologia 1993;36:1215-1217
7. Matschinsky F, Liang Y, Kesavan P, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 1993;92:2092-2098
8. Kang L, Dunn-Meynell AA, Routh VH, et al. Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing. Diabetes 2006;55:412-420
9. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1-18
10. Velho G, Froguel P, Clement K, et al. Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet 1992;340:444-448
11. Byrne MM, Sturis J, Fajans SS, et al. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 1995;44:699-704
12. Byrne MM, Sturis J, Clément K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994;93:1120-1130
13. Velho G, Petersen KF, Perseghin G, et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest 1996;98:1755-1761
14. Clément K, Pueyo ME, Vaxillaire M, et al. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 1996;39:82-90
15. Tappy L, Dussoix P, Iynedjian P, et al. Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene. Diabetes 1997;46:204-208
16. Steele AM, Wensley KJ, Ellard S, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS ONE 2013;8:e65326
17. Prisco F, Iafusco D, Franzese A, Sulli N, Barbetti F. MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of "neonatal diabetes"? Diabetologia 2000;43:1331-1332
18. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275-1281
19. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014;311:279-286
20. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980
21. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-213
22. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011;343:d6044
23. Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care 2014;37:1230-1236
24. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504-2508
25. Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014;57:54-56
26. Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P. Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care 1996;19:915-919
27. Velho G, Blanché H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40:217-224
28. Costa A, Bescós M, Velho G, et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 2000;142:380-386
29. Lorini R, Klersy C, d'Annunzio G, et al, .; Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009;32:1864-1866
30. Lehto M, Wipemo C, Ivarsson SA, et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia 1999;42:1131-1137
31. Sagen JV, Bjørkhaug L, Molnes J, et al. Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry. Pediatr Diabetes 2008;9:442-449
32. Fendler W, Borowiec M, Baranowska-Jazwiecka A, et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia 2012;55:2631-2635
33. Hager J, Blanché H, Sun F, et al. Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique. Diabetes 1994;43:730-733
34. Kousta E, Ellard S, Allen LI, et al. Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes. Diabet Med 2001;18:683-684
35. Shimada F, Makino H, Hashimoto N, et al. Type 2 (non-insulin-dependent) diabetes mellitus associated with a mutation of the glucokinase gene in a Japanese family. Diabetologia 1993;36:433-437
36. Xu JY, Dan QH, Chan V, et al. Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet 2005;13:422-427
37. Hwang JS, Shin CH, Yang SW, Jung SY, Huh N. Genetic and clinical characteristics of Korean maturity-onset diabetes of the young (MODY) patients. Diabetes Res Clin Pract 2006;74:75-81
38. Porter JR, Rangasami JJ, Ellard S, et al. Asian MODY: are we missing an important diagnosis? Diabet Med 2006;23:1257-1260
39. Kawakita R, Hosokawa Y, Fujimaru R, et al. Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients. Diabet Med 2014;31:1357-1362
40. Feigerlová E, Pruhová S, Dittertová L, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr 2006;165:446-452
41. Codner E, Rocha A, Deng L, et al. Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. Pediatr Diabetes 2009;10:382-388
42. Schober E, Rami B, Grabert M, et al, .; DPV-Wiss Initiative of the German Working Group for Paediatric Diabetology and. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009;26:466-473
43. Massa O, Meschi F, Cuesta-Munoz A, et al, .; Diabetes Study Group of the Italian Society of Paediatic Endocrinology and Diabetes (SIEDP). High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetologia 2001;44:898-905
44. Yorifuji T, Fujimaru R, Hosokawa Y, et al. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes 2012;13:26-32
45. Gloyn AL, van de Bunt M, Stratton IM, et al. Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia. Diabetologia 2009;52:172-174
46. Ellard S, Beards F, Allen LI, et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 2000;43:250-253
47. Stoffel M, Bell KL, Blackburn CL, et al. Identification of glucokinase mutations in subjects with gestational diabetes mellitus. Diabetes 1993;42:937-940
48. Zouali H, Vaxillaire M, Lesage S, et al. Linkage analysis and molecular scanning of glucokinase gene in NIDDM families. Diabetes 1993;42:1238-1245
49. Saker PJ, Hattersley AT, Barrow B, et al. High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population. Diabetologia 1996;39:1325-1328
50. Zaidi FK, Wareham NJ, McCarthy MI, et al. Homozygosity for a common polymorphism in the islet-specific promoter of the glucokinase gene is associated with a reduced early insulin response to oral glucose in pregnant women. Diabet Med 1997;14:228-234
51. Chiu KC, Go RC, Aoki M, et al. Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning. Diabetologia 1994;37:104-110
52. Allan CJ, Argyropoulos G, Bowker M, et al. Gestational diabetes mellitus and gene mutations which affect insulin secretion. Diabetes Res Clin Pract 1997;36:135-141
53. Frigeri HR, Santos IC, Réa RR, et al. Low prevalence of glucokinase gene mutations in gestational diabetic patients with good glycemic control. Genet Mol Res 2012;11:1433-1441
54. Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002;45:427-435
55. Pearson ER, Velho G, Clark P, et al. beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 2001;50(Suppl. 1):S101-S107
56. Guenat E, Seematter G, Philippe J, Temler E, Jequier E, Tappy L. Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab 2000;26:377-384
57. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28:1028-1033
58. Besser RE, Shepherd MH, McDonald TJ, et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-alpha/hepatocyte nuclear factor 4-alpha maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:286-291
59. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012;55:1265-1272
60. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512-1526
61. Valentínová L, Beer NL, Staník J, et al. Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia. PLoS ONE 2012;7:e34541
62. Gasperíková D, Tribble ND, Staník J, et al. Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. Diabetes 2009;58:1929-1935
63. Ellard S, Thomas K, Edghill EL, et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 2007;50:2313-2317
64. Garin I, Rica I, Estalella I, et al, .; Spanish MODY Group. Haploinsufficiency at GCK gene is not a frequent event in MODY2 patients. Clin Endocrinol (Oxf) 2008;68:873-878
65. Cappelli A, Silvestri S, Tumini S, et al. A new de novo mutation in the GCK gene causing MODY2. Diabetes Res Clin Pract 2011;93:e41-e43
66. Birkebaek NH, Sorensen JS, Vikre-Jorgensen J, Jensen PK, Pedersen O, Hansen T. A de novo whole GCK gene deletion not detected by gene sequencing, in a boy with phenotypic GCK insufficiency. Case Rep Genet 2011;2011:768610
67. Stanik J, Dusatkova P, Cinek O, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 2014;57:480-484
68. Raimondo A, Chakera AJ, Thomsen SK, et al.; International NDM Consortium. Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. Hum Mol Genet 2014
69. Liang Y, Najafi H, Smith RM, et al. Concordant glucose induction of glucokinase, glucose usage, and glucose-stimulated insulin release in pancreatic islets maintained in organ culture. Diabetes 1992;41:792-806
70. Sturis J, Kurland IJ, Byrne MM, et al. Compensation in pancreatic beta-cell function in subjects with glucokinase mutations. Diabetes 1994;43:718-723
71. Burke CV, Buettger CW, Davis EA, McClane SJ, Matschinsky FM, Raper SE. Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI). Biochem J 1999;342:345-352
72. Steele AM, Tribble ND, Caswell R, et al. The previously reported T342P GCK missense variant is not a pathogenic mutation causing MODY. Diabetologia 2011;54:2202-2205
73. Page RC, Hattersley AT, Levy JC, et al. Clinical characteristics of subjects with a missense mutation in glucokinase. Diabet Med 1995;12:209-217
74. Fendler W, Rizzo M, Borowiec M, et al. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol 2014;51:625-632
75. Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 1998;19:268-270
76. Velho G, Hattersley AT, Froguel P. Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on adult weight, height, insulin secretion or insulin sensitivity. Diabetologia 2000;43:1060-1063
77. Spyer G, Macleod KM, Shepherd M, Ellard S, Hattersley AT. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 2009;26:14-18
78. Pedersen J. The Pregnant Diabetic and Her Newborn: Problems and Management. Copenhagen, Denmark, Munksgaard, 1967
79. Metzger BE, Lowe LP, Dyer AR, et al, .; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002
80. de Las Heras J, Martínez R, Rica I, de Nanclares GP, Vela A, Castaño L; Spanish MODY group. Heterozygous glucokinase mutations and birth weight in Spanish children. Diabet Med 2010;27:608-610
81. Singh R, Pearson ER, Clark PM, Hattersley AT. The long-term impact on offspring of exposure to hyperglycaemia in utero due to maternal glucokinase gene mutations. Diabetologia 2007;50:620-624
82. Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol 2001;185:240-241
83. Chakera AJ, Carleton VL, Ellard S, et al. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment. Diabetes Care 2012;35:1832-1834
84. Buchanan TA, Kjos SL, Montoro MN, et al. Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care 1994;17:275-283
85. Kjos SL, Schaefer-Graf U, Sardesi S, et al. A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Diabetes Care 2001;24:1904-1910
86. Schaefer-Graf UM, Kjos SL, Fauzan OH, et al. A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in Caucasian women. Diabetes Care 2004;27:297-302
87. Silva JC, Pacheco C, Bizato J, de Souza BV, Ribeiro TE, Bertini AM. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynaecol Obstet 2010;111:37-40
88. Caritis SN, Hebert MF. A pharmacologic approach to the use of glyburide in pregnancy. Obstet Gynecol 2013;121:1309-1312
89. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350:h102
90. Owen K, Hattersley AT. Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab 2001;15:309-323
91. World Health Organization. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva, World Health Org., 2013 (WHO/NMH/MND/13.2)